China Has More CAR-T Trials Than America. Your Patients Are Still Waiting.
For many oncologists and pharma representatives in Southeast Asia, China is still not the first destination that comes to mind when a patient asks about advanced cellular therapy.
That gap in perception is becoming harder to justify.
Peer-reviewed sources show that China leads the world in CAR-T trial activity, with 1,006 trials compared with 549 in the United States. For patients who have exhausted standard options, that scale matters. It can mean more treatment centers, more clinical experience, and more possible routes to a second opinion.
Why the referral conversation is changing
CAR-T treatment access is not only a question of science. It is also a question of time, manufacturing capacity, and cost.
The published sources point to several developments:
- China leads global CAR-T trial volume, with 1,006 trials versus 549 in the United States.
- FasTCAR manufacturing compressed production timelines to 24 hours in research published in Blood Cancer Journal.
- The RELIANCE study reported 66.7% four-year overall survival for relapsed or refractory large B-cell lymphoma.
- Reported CAR-T costs in China were about $188,000-$200,000, compared with $1,000,000 or more in the United States.
- Chinese Malaysians account for 53% of all lymphoma cases in Malaysia’s national registry data.
These claims do not mean China is the right answer for every patient. They do mean that China should be part of the discussion when patients and physicians are evaluating advanced options.
What this means for Southeast Asia
For Chinese communities in Malaysia, Singapore, and Indonesia, China is not just another medical travel destination. There are cultural, linguistic, and family ties that can make the care journey easier to understand and coordinate.
The question is not whether every patient should travel. The question is whether patients who are waiting, relapsing, or running out of options deserve to know that China may have relevant clinical capacity.
SinoBridge Health exists to make that conversation clearer. We help patients and referring professionals understand which hospitals may be appropriate, what documentation is needed, and what a realistic referral process can look like.
Sources
- Biomarker Research, Springer Nature, March 2026
- Blood Cancer Journal, Nature, 2022
- Journal of Clinical Oncology, ASCO 2024
- Journal of Medical Economics, 2023
- Malaysia National Cancer Registry
This article is informational only. Treatment eligibility and clinical decisions must be made with qualified physicians.